Universal Vision Biotechnology Co., Ltd. (TPEX: 3218)
Taiwan
· Delayed Price · Currency is TWD 210.00
-2.50 (-1.18%)
Nov 21, 2024, 9:59 AM CST
Universal Vision Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 4,165 | 4,082 | 3,494 | 2,632 | 2,053 | 1,419 | Upgrade
|
| Revenue Growth (YoY) | 6.88% | 16.83% | 32.76% | 28.18% | 44.69% | 18.75% | Upgrade
|
| Cost of Revenue | 1,665 | 1,634 | 1,354 | 995.36 | 785.99 | 601.91 | Upgrade
|
| Gross Profit | 2,500 | 2,448 | 2,140 | 1,636 | 1,267 | 817.07 | Upgrade
|
| Selling, General & Admin | 1,145 | 1,132 | 1,051 | 867.59 | 670.63 | 570.22 | Upgrade
|
| Operating Expenses | 1,146 | 1,137 | 1,059 | 867.91 | 670.63 | 570.02 | Upgrade
|
| Operating Income | 1,355 | 1,312 | 1,081 | 768.54 | 596.52 | 247.04 | Upgrade
|
| Interest Expense | -16.8 | -15.83 | -13.56 | -13.16 | -10.94 | -12.18 | Upgrade
|
| Interest & Investment Income | 22.98 | 19.16 | 6.93 | 4.07 | 4.84 | 7.9 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.8 | -0.06 | 9.8 | -2.57 | -0.91 | 1.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.92 | 3.59 | 9.6 | 6.03 | 8.84 | 6.39 | Upgrade
|
| EBT Excluding Unusual Items | 1,372 | 1,319 | 1,094 | 762.91 | 598.35 | 250.34 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.03 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.86 | -1.37 | -2.22 | -0.22 | 3.28 | 4.07 | Upgrade
|
| Other Unusual Items | 0.01 | 1.23 | 0.41 | 0.42 | 0.5 | 0.03 | Upgrade
|
| Pretax Income | 1,372 | 1,319 | 1,092 | 763.11 | 602.13 | 255.04 | Upgrade
|
| Income Tax Expense | 273.52 | 254.56 | 223.98 | 152.45 | 117.98 | 63.32 | Upgrade
|
| Earnings From Continuing Operations | 1,098 | 1,064 | 868.11 | 610.66 | 484.15 | 191.72 | Upgrade
|
| Minority Interest in Earnings | 3.06 | -18.93 | -17.58 | -15.23 | -0.94 | 46.29 | Upgrade
|
| Net Income | 1,101 | 1,045 | 850.53 | 595.43 | 483.21 | 238.01 | Upgrade
|
| Net Income to Common | 1,101 | 1,045 | 850.53 | 595.43 | 483.21 | 238.01 | Upgrade
|
| Net Income Growth | 12.81% | 22.88% | 42.84% | 23.22% | 103.03% | 47.39% | Upgrade
|
| Shares Outstanding (Basic) | 85 | 85 | 85 | 85 | 85 | 85 | Upgrade
|
| Shares Outstanding (Diluted) | 85 | 85 | 85 | 85 | 85 | 85 | Upgrade
|
| Shares Change (YoY) | 0.08% | 0.04% | 0.03% | -0.04% | -0.10% | -0.12% | Upgrade
|
| EPS (Basic) | 13.00 | 12.34 | 10.04 | 7.03 | 5.70 | 2.81 | Upgrade
|
| EPS (Diluted) | 12.97 | 12.31 | 10.02 | 7.02 | 5.70 | 2.80 | Upgrade
|
| EPS Growth | 12.76% | 22.85% | 42.76% | 23.22% | 103.21% | 47.86% | Upgrade
|
| Free Cash Flow | 1,121 | 1,081 | 778.47 | 587.33 | 531.93 | 184 | Upgrade
|
| Free Cash Flow Per Share | 13.20 | 12.73 | 9.17 | 6.92 | 6.27 | 2.17 | Upgrade
|
| Dividend Per Share | 7.000 | 7.000 | 5.660 | 4.492 | 3.774 | 1.797 | Upgrade
|
| Dividend Growth | 23.67% | 23.67% | 26.00% | 19.05% | 110.01% | 59.99% | Upgrade
|
| Gross Margin | 60.03% | 59.98% | 61.24% | 62.18% | 61.72% | 57.58% | Upgrade
|
| Operating Margin | 32.52% | 32.14% | 30.94% | 29.20% | 29.05% | 17.41% | Upgrade
|
| Profit Margin | 26.44% | 25.60% | 24.34% | 22.62% | 23.54% | 16.77% | Upgrade
|
| Free Cash Flow Margin | 26.92% | 26.48% | 22.28% | 22.32% | 25.91% | 12.97% | Upgrade
|
| EBITDA | 1,661 | 1,592 | 1,295 | 942.85 | 740 | 372.7 | Upgrade
|
| EBITDA Margin | 39.89% | 38.99% | 37.06% | 35.83% | 36.04% | 26.27% | Upgrade
|
| D&A For EBITDA | 306.9 | 279.84 | 213.63 | 174.32 | 143.48 | 125.66 | Upgrade
|
| EBIT | 1,355 | 1,312 | 1,081 | 768.54 | 596.52 | 247.04 | Upgrade
|
| EBIT Margin | 32.52% | 32.14% | 30.94% | 29.20% | 29.05% | 17.41% | Upgrade
|
| Effective Tax Rate | 19.94% | 19.31% | 20.51% | 19.98% | 19.59% | 24.83% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.